Peptide And Oligonucleotide Cdmo Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Peptide and oligonucleotide CDMOs offer end-to-end services spanning process development, clinical and commercial-scale manufacturing, analytical testing, and regulatory support for large-molecule therapeutics. The market encompasses custom synthesis of peptides for applications including oncology, metabolic disorders, and infectious diseases, as well as oligonucleotides for gene therapies and RNA-based medicines. The industry has attracted significant interest due to the technical barriers involved in producing these complex molecules at scale, making specialized contract manufacturing increasingly essential.

• •Market estimated at $2.79 billion in 2025 with projections varying between $4.03 billion and $5.0 billion by 2030 depending on the source
• •No official government statistical agency publishes dedicated market size statistics for this specialized sector
• •The US market alone is forecast to reach approximately $2.53 billion by 2033

A robust pipeline of peptide and oligonucleotide drugs in clinical development, combined with an accelerating pace of regulatory approvals, is the primary engine of market expansion. The technical complexity of manufacturing these molecules, which requires specialized equipment, stringent quality controls, and expert scientific knowledge, makes in-house production challenging for many pharmaceutical and biotechnology companies. Rising prevalence of chronic and rare diseases treatable with these modalities further fuels demand for CDMO services.

• •Increasing number of FDA and EMA approvals for peptide and oligonucleotide-based therapeutics
• •Rising adoption of personalized medicine and targeted therapies requiring complex molecular synthesis
• •Growing trend of pharmaceutical outsourcing to reduce capital expenditure and accelerate time-to-market

The market is broadly segmented by product type, including peptides used in therapeutics and diagnostics, and oligonucleotides encompassing antisense oligonucleotides, siRNA, and aptamers. Service categories span process development, preclinical and clinical manufacturing, and commercial-scale production. Geographically, North America leads the market, supported by a high concentration of biopharmaceutical companies, favorable regulatory frameworks, and substantial R&D investment, while the Asia-Pacific region is expanding rapidly due to cost advantages and growing manufacturing capabilities.

• •United States represents the largest single-country market, expected to reach $2.53 billion by 2033
• •Asia-Pacific emerging as a fast-growing region driven by manufacturing cost advantages
• •Service segments include process development, clinical manufacturing, and commercial production

What are the recent trends and outlook?

Technological advancements in continuous manufacturing, flow chemistry, and solid-phase synthesis are improving production efficiency and reducing costs, while companies are expanding capacity through new facility investments and strategic acquisitions. The convergence of peptide and oligonucleotide technologies, along with growing interest in conjugate drugs combining these modalities with antibodies or small molecules, is creating new opportunities for CDMOs with integrated capabilities. Long-term market projections remain positive as the biopharmaceutical pipeline continues to mature and the strategic importance of specialized contract manufacturing grows.

• •Market projected to reach between $4.03 billion and $5.0 billion globally by 2030
• •Continued expansion of manufacturing capacity through new facility construction and technology upgrades
• •Growing integration of peptide and oligonucleotide services as conjugate drugs and combination therapies gain prominence